Modality
Nanobody
MOA
HER2
Target
IL-17A
Pathway
Notch
CF
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
~Nov 2018
→ ~Feb 2020
NDA/BLA
May 2020
→ Mar 2027
NDA/BLACurrent
NCT07519913
2,239 pts·CF
2021-09→2026-08·Completed
NCT08743710
643 pts·CF
2020-05→2027-03·Not yet recruiting
2,882 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-114mo awayPh3 Readout· CF
2027-03-1211mo awayPh3 Readout· CF
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
NDA/BLA
Not yet…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-08-11 · 4mo away
CF
Ph3 Readout
2027-03-12 · 11mo away
CF
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07519913 | NDA/BLA | CF | Completed | 2239 | OS |
| NCT08743710 | NDA/BLA | CF | Not yet recr... | 643 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |